Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL.

Published

Journal Article

PD-1/L1 and CTLA-4 blockade immunotherapies have been approved for 13 types of cancers and are being studied in diffuse large B-cell lymphoma (DLBCL), the most common aggressive B-cell lymphoma. However, whether both PD-1 and CTLA-4 checkpoints are active and clinically significant in DLBCL is unknown. Whether PD-1 ligands expressed by tumor cells or by the microenvironment of DLBCL are critical for the PD-1 immune checkpoint is unclear. We performed immunophenotypic profiling for 405 patients with de novo DLBCL using a MultiOmyx immunofluorescence platform and simultaneously quantitated expression/coexpression of 13 immune markers to identify prognostic determinants. In both training and validation cohorts, results demonstrated a central role of the tumor immune microenvironment, and when its functionality was impaired by deficiency in tumor-infiltrating T cells and/or natural killer cells, high PD-1 expression (but not CTLA-4) on CD8+ T cells, or PD-L1 expression on T cells and macrophages, patients had significantly poorer survival after rituximab-CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) immunochemotherapy. In contrast, tumor-cell PD-L2 expression was associated with superior survival, as well as PD-L1+CD20+ cells proximal (indicates interaction) to PD-1 + CD8+ T cells in patients with low PD-1 + percentage of CD8+ T cells. Gene-expression profiling results suggested the reversibility of T-cell exhaustion in PD-1+/PD-L1+ patients with unfavorable prognosis and implication of LILRA/B, IDO1, CHI3L1, and SOD2 upregulation in the microenvironment dysfunction with PD-L1 expression. This study comprehensively characterized the DLBCL immune landscape, deciphered the differential roles of various checkpoint components in rituximab-CHOP resistance in DLBCL patients, and suggests targets for PD-1/PD-L1 blockade and combination immunotherapies.

Full Text

Duke Authors

Cited Authors

  • Xu-Monette, ZY; Xiao, M; Au, Q; Padmanabhan, R; Xu, B; Hoe, N; Rodríguez-Perales, S; Torres-Ruiz, R; Manyam, GC; Visco, C; Miao, Y; Tan, X; Zhang, H; Tzankov, A; Wang, J; Dybkær, K; Tam, W; You, H; Bhagat, G; Hsi, ED; Ponzoni, M; Ferreri, AJM; Møller, MB; Piris, MA; van Krieken, JH; Winter, JN; Westin, JR; Pham, LV; Medeiros, LJ; Rassidakis, GZ; Li, Y; Freeman, GJ; Young, KH

Published Date

  • April 2019

Published In

Volume / Issue

  • 7 / 4

Start / End Page

  • 644 - 657

PubMed ID

  • 30745366

Pubmed Central ID

  • 30745366

Electronic International Standard Serial Number (EISSN)

  • 2326-6074

International Standard Serial Number (ISSN)

  • 2326-6066

Digital Object Identifier (DOI)

  • 10.1158/2326-6066.cir-18-0439

Language

  • eng